PFIZER Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?
PFIZER has one hundred and ninety-four approved drugs.
There are forty-eight US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand and twenty-one patent family members on PFIZER drugs in seventy countries and two hundred and fifty-nine supplementary protection certificates in nineteen countries.
Summary for PFIZER
International Patents: | 1021 |
US Patents: | 48 |
Tradenames: | 159 |
Ingredients: | 130 |
NDAs: | 194 |
Drug Master File Entries: | 3 |
Patent Litigation for PFIZER: | See patent lawsuits for PFIZER |
PTAB Cases with PFIZER as petitioner: | See PTAB cases with PFIZER as petitioner |
Drugs and US Patents for PFIZER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | CIBINQO | abrocitinib | TABLET;ORAL | 213871-003 | Jan 14, 2022 | RX | Yes | Yes | 9,035,074 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Pfizer | DOXORUBICIN HYDROCHLORIDE | doxorubicin hydrochloride | INJECTABLE;INJECTION | 050629-003 | Mar 28, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pfizer Inc | CAMPTOSAR | irinotecan hydrochloride | INJECTABLE;INJECTION | 020571-003 | Aug 5, 2010 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | CLEOCIN PHOSPHATE | clindamycin phosphate | INJECTABLE;INJECTION | 050441-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | MEDROL | methylprednisolone | TABLET;ORAL | 011153-004 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | TROXYCA ER | naltrexone hydrochloride; oxycodone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 207621-003 | Aug 19, 2016 | DISCN | No | No | 7,815,934 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PFIZER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | 5,082,668 | ⤷ Try a Trial |
Pfizer | CYTOTEC | misoprostol | TABLET;ORAL | 019268-003 | Sep 21, 1990 | 4,301,146 | ⤷ Try a Trial |
Pfizer | AROMASIN | exemestane | TABLET;ORAL | 020753-001 | Oct 21, 1999 | 4,904,650 | ⤷ Try a Trial |
Pfizer | GLUCOTROL XL | glipizide | TABLET, EXTENDED RELEASE;ORAL | 020329-002 | Apr 26, 1994 | 5,591,454 | ⤷ Try a Trial |
Pfizer | CYTOTEC | misoprostol | TABLET;ORAL | 019268-001 | Dec 27, 1988 | 4,060,691 | ⤷ Try a Trial |
Pfizer | MINIZIDE | polythiazide; prazosin hydrochloride | CAPSULE;ORAL | 017986-003 | Approved Prior to Jan 1, 1982 | 4,130,647 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2005-12-21 |
➤ Subscribe | Injection | 2 mg/mL, 300 mL bag | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Tablets | 1 g | ➤ Subscribe | 2005-08-23 |
➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Oral Suspension | 100 mg/5 mL | ➤ Subscribe | 2009-08-03 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL bag | ➤ Subscribe | 2009-12-29 |
International Patents for PFIZER Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Poland | 218519 | ⤷ Try a Trial |
Canada | 2900322 | ⤷ Try a Trial |
Nicaragua | 200300008 | ⤷ Try a Trial |
South Korea | 20170081737 | ⤷ Try a Trial |
Eurasian Patent Organization | 006227 | ⤷ Try a Trial |
Dominican Republic | P2023000168 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PFIZER Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2822953 | 2019034 | Norway | ⤷ Try a Trial | PRODUCT NAME: LORLATINIB; REG. NO/DATE: EU/1/19/1355 20190523 |
2767537 | 1990055-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: TALAZOPARIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/19/1377 20190624 |
0266730 | 98C0014 | Belgium | ⤷ Try a Trial | PRODUCT NAME: MIGLITOL; NAT. REGISTRATION NO/DATE: NL 22 138 19970204; FIRST REGISTRATION: NL - 19 343 UR 19960723 |
0139421 | SPC/GB97/084 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TROGLITAZONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 10949/0277 19970729; UK 10949/0278 19970729; UK 10949/0279 19970729; UK 06384/0005 19970729; UK 06384/0006 19970729; UK 06384/0007 19970729 |
1470124 | 132017000046148 | Italy | ⤷ Try a Trial | PRODUCT NAME: PALBOCICLIB, OPZIONALMENTE NELLA FORMA DI UN SALE, ESTERE, AMMIDE O PROFARMACO FARMACEUTICAMENTE ACCETTABILE(IBRANCE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1147/001-006, 20161111 |
1848414 | CA 2016 00033 | Denmark | ⤷ Try a Trial | PRODUCT NAME: OSIMERTINIB; REG. NO/DATE: EU/1/16/1086/001-0002 20160204 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.